Phase 4 N=10 Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
HIV Infections · Hepatitis B
Primary: Hepatitis B Virus (HBV) DNA — 2.4; 0.8 log 10 IU/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Vorinostat in Treating Patients With Acute Myeloid Leukemia
Adult Acute Erythroid Leukemia (M6) · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Confirmed Complete Response (CR) Rate — 0; 4.5 percentage of participants
Phase 2 N=233 To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
Tuberculosis
Primary: The Median Time to Sputum Culture Conversion — 57 Days
Phase 2 N=8 A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Hepatitis C Infection · HIV Infection
Primary: Number of Participants With Adverse Events — 8 participants
Phase 2 N=24 Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
Lung Cancer
Primary: Number of Evaluable Participants With Tumor Response — 5 participants
N/A N=17 Immediate Postmastectomy Breast Reconstruction (Strattice Breast)
Breast Cancer
Primary: Histology Sample Evaluations Assessing Incorporation of StratticeTM Reconstructive Tissue Matrix — 0; 82.8; 17.2; 0 percentage of breasts
Phase 3 N=86 Topical Radial Artery Vasodilation
Cardiac Catheterization · Spasm
Primary: Change in Radial Artery Diameter — -5.6; 16.5 Percent change
Phase 4 N=31 Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
Urinary Bladder, Overactive
Primary: Mean Number of Micturition-Related Urgency Episodes Per 24 Hours (End of Treatment [EOT]) — 5.48 episodes per 24 hours
Phase 4 N=126 Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Inspiratory Capacity (IC) at Isotime — 0.0035; 0.07 liter — p=0.0087
Phase 2 N=45 Effect of Electrical Stimulation (DC Polarization) to the Brain on Memory
Healthy
Primary: Verbal Memory — 8.625; 9; 8 Words recalled — p=>0.05
N/A N=362 Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan
Diabetes
Primary: Changes in the Physical Component Summary of the SF-12 Health Survey — 1.3; -0.7 units on a scale — p=0.03
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 1 N=15 Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Hematologic Malignancy · Malignant Lymphoma
Primary: Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin — 911.0; 1020.7 ng*hr/mL
Phase 3 N=20 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
Intestinal Behçet's Disease
Primary: Number of Participants With Marked Improvement at Week 24 — 9 participants
N/A N=36 Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP)
Sleep Apnea, Obstructive
Primary: Sleep/Wake Algorithm — 62 accuracy (%)